Patient-reported outcomes: central to the management of COVID-19

被引：25
作者：
Aiyegbusi, Olalekan Lee [1 ]
Calvert, Melanie J. [1 ,2 ,3 ]
机构：
[1] Univ Birmingham, Ctr Patient Reported Outcomes Res, Inst Appl Hlth Res, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Birmingham Hlth Partners Ctr Regulatory Sci & Inn, Birmingham B15 2TT, W Midlands, England
[3] Univ Birmingham, Natl Inst Hlth Res Birmingham Biomed Res Ctr, Birmingham, W Midlands, England
来源：
LANCET | 2020年 / 396卷 / 10250期
关键词：
D O I：
10.1016/S0140-6736(20)31724-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：531 / 531
页数：1
相关论文
共 5 条
[1]   Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment [J].
Basch, Ethan ;
Deal, Allison M. ;
Dueck, Amylou C. ;
Scher, Howard I. ;
Kris, Mark G. ;
Hudis, Clifford ;
Schrag, Deborah .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (02) :197-198
[2]   Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [J].
Dueck, Amylou C. ;
Mendoza, Tito R. ;
Mitchell, Sandra A. ;
Reeve, Bryce B. ;
Castro, Kathleen M. ;
Rogak, Lauren J. ;
Atkinson, Thomas M. ;
Bennett, Antonia V. ;
Denicoff, Andrea M. ;
O'Mara, Ann M. ;
Li, Yuelin ;
Clauser, Steven B. ;
Bryant, Donna M. ;
Bearden, James D., III ;
Gillis, Theresa A. ;
Harness, Jay K. ;
Siegel, Robert D. ;
Paul, Diane B. ;
Cleeland, Charles S. ;
Schrag, Deborah ;
Sloan, Jeff A. ;
Abernethy, Amy P. ;
Bruner, Deborah W. ;
Minasian, Lori M. ;
Basch, Ethan .
JAMA ONCOLOGY, 2015, 1 (08) :1051-1059
[3]   Virtually Perfect? Telemedicine for Covid-19 [J].
Hollander, Judd E. ;
Carr, Brendan G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (18) :1679-1681
[4]   Planning for a COVID-19 Vaccination Program [J].
Schaffer DeRoo, Sarah ;
Pudalov, Natalie J. ;
Fu, Linda Y. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (24) :2458-2459
[5]   Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial [J].
Zhu, Feng-Cai ;
Li, Yu-Hua ;
Guan, Xu-Hua ;
Hou, Li-Hua ;
Wang, Wen-Juan ;
Li, Jing-Xin ;
Wu, Shi-Po ;
Wang, Bu-Sen ;
Wang, Zhao ;
Wang, Lei ;
Jia, Si-Yue ;
Jiang, Hu-Dachuan ;
Wang, Ling ;
Jiang, Tao ;
Hu, Yi ;
Gou, Jin-Bo ;
Xu, Sha-Bei ;
Xu, Jun-Jie ;
Wang, Xue-Wen ;
Wang, Wei ;
Chen, Wei .
LANCET, 2020, 395 (10240) :1845-1854
1